Therapy | Target | Agents | Species | Subpopulation | Treatment regimen | Efficiency | Reference |
---|---|---|---|---|---|---|---|
New anti-EGFR mAbs | EGFR ECD | GC1118 | PDXs | KRAS mutation | GC1118 VS cetuximab | Sensitive VS insensitive | [40] |
MM-151 | PDXs | EGFR G465E | MM-151 VS cetuximab/panitumumab | Sensitive VS insensitive | [41] | ||
MEK inhibitor | MEK | Pimasertib | Cell | / | Pimasertib + cetuximab | Sensitive VS insensitive | [42] |
ERBB2 mABs | ERBB2 | 4D5 | Cell | / | 4D5+ cetuximab VS cetuximab | Sensitive VS insensitive | [43] |
Trastuzumab | Cell | / | Trastuzumab + cetuximab VS cetuximab | Sensitive VS insensitive | [44] | ||
PI3K inhibitor | PI3K | BKM120 | Cell/nude mice | KRAS mutation | Cetuximab + BKM120 VS cetuximab VS BKM120 | More effective | [45] |
MET inhibitor | MET | Crizotinib | Cell | KRAS mutation | Crizotinib VS cetuximab | Sensitive VS insensitive | [46] |
Metabolic regulators | AMPK | Metformin | Cell/ mice | KRAS mutation | Metformin+ cetuximab VS cetuximab | Sensitive VS insensitive | [47] |
Metabolic regulators | Methylglyoxal | Carnosine | Cell/mice | KRAS mutation | Carnosine + cetuximab VS cetuximab | Sensitive VS insensitive | [48] |
Metabolic regulators | BRAF | Simvastatin | Cell/mice | KRAS mutation | Simvastatin + cetuximab VS cetuximab | mean tumor volume: 20.2vs 49.4cm3 | [49] |
Metabolic regulators | Glutaminase 1 | CB-839 | Cell/mice | KRAS WT | CB-839 + cetuximab VS cetuximab | Sensitive VS insensitive | [50] |
Metabolic regulators | RAF | L-ascorbic acid | Cell/mice | KRAS mutation | L-ascorbic acid + cetuximab VS cetuximab | Sensitive VS insensitive | [51] |
Immunity therapy | NK cells | anti-CD137 mAb | Mice | KRAS WT/mutaion | anti-CD137 mAb + cetuximab | Tumor regression and prolonged survival | [52] |
UCB-NK | Cell | EGFR (+) RAS mutation | UCB-NK + cetuximab | Sensitive VS insensitive | [53] | ||
Immunity therapy | T cells | BiTE | Cell | RAS and RAF mutation | BiTE+ cetuximab vs cetuximab | Sensitive VS insensitive | [54] |
Immunity therapy | TLR9 | IMO | Cell | KRAS mutation | IMO + cetuximab VS cetuximab | Sensitive VS insensitive | |
Immunity therapy | CAFs | Regorafenib | Cell/ nude mice | Unselected | Regorafenib + cetuximab | Sensitive VS insensitive | [57] |
BLU9931 | Cell | Unselected | BLU9931 + cetuximab VS cetuximab | Sensitive VS insensitive | [58] | ||
Cytotoxic drugs | / | TAS-102 | PDXs | / | TAS-102+Panitumumab | Response | [59] |
Natural bioactive monomer | / | β-elemene | Cell / mice | KRAS mutation | β-elemene + cetuximab VS cetuximab | Tumor growth inhibition and less lymph node metastasis | [60] |